Evaluation of Luminescent P450 Analysis for Directed Evolution of Human CYP4A11

Seunghye Choi¹, Songhee Han¹, Hwayoun Lee¹, Young-Jin Chun² and Donghak Kim¹,*

¹Department of Biological Sciences, Konkuk University, Seoul 143-701, ²College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea

Abstract
Cytochrome P450 4A11 (CYP4A11) is a fatty acid hydroxylase enzyme expressed in human liver. It catalyzes not only the hydroxylation of saturated and unsaturated fatty acids, but the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a regulator of blood pressure. In this study, we performed a directed evolution analysis of CYP4A11 using the luminogenic assay system. A random mutant library of CYP4A11, in which mutations were made throughout the entire coding region, was screened with luciferase activity to detect the demethylation of luciferin-4A (2-[6-methoxyquinolin-2-yl]-4,5-dihydrothiazole-4-carboxylic acid) of CYP4A11 mutants in Escherichia coli. Consecutive rounds of random mutagenesis and screening yielded three improved CYP4A11 mutants, CP2600 (A24T/T263A), CP2601 (T263A), and CP2616 (A24T/T263A/V430E) with ~3-fold increase in whole cells and >10-fold increase in purified proteins on the luminescence assay. However, the steady state kinetic analysis for lauric acid hydroxylation showed the significant reductions in enzymatic activities in all three mutants. A mutant, CP2600, showed a 51% decrease in catalytic efficiency (kcat/Km) for lauric acid hydroxylation mainly due to an increase in Km. CP2601 and CP2616 showed much greater reductions (>75%) in the catalytic efficiency due to both a decrease in kcat and an increase in Km. These decreased catalytic activities of CP2601 and CP2616 can be partially attributed to the changes in substrate affinities. These results suggest that the enzymatic activities of CYP4A11 mutants selected from directed evolution using a luminogenic P450 substrate may not demonstrate a direct correlation with the hydroxylation activities of lauric acid.

Key Words: P450, CYP4A11, Luciferin, Lauric acid, GC-mass spectrometry

INTRODUCTION
Cytochrome P450s (CYPs, P450s) comprise the superfamily of heme-containing oxidoreductase enzymes found in various organisms including animals, plants, fungi and bacteria (Ortiz de Montellano, 2005). In humans, CYPs are responsible for the metabolism of various endogenous and exogenous chemicals including drugs (Guenigerich, 2005). Among 57 human CYPs, CYP4A11 is a major fatty acid hydroxylase found in human liver (Guenigerich, 2005). It catalyzes the hydroxylation of saturated and unsaturated fatty acids mainly at the terminal carbon position and therefore converts lauric acid to 12-hydroxylauric acid (Okita and Okita, 2001; He et al., 2005). This terminal hydroxylation of fatty acids is considered to maintain the balance of lipids in human liver (Adas et al., 1999). It is also involved in the terminal oxidation reaction of arachidonic acid to produce 20-hydroxyeicosatetraenoic acid (20-HETE), which known as a regulator of blood pressure (Gainer et al., 2005). The production of 20-HETE is relatively unique among the human P450s and therefore, the regulation of CYP4A11 activity can suggest a new therapeutic approach to control hypertension.

Random mutagenesis and subsequent screening (so-called directed evolution) is an effective tool to engineer enzymes or to investigate structure-function relationships of proteins. CYP enzymes have been gaining particular attention for their applications in biotransformation and in the study of structure-function relationships (Kim et al., 2005). In previous studies, the formations of dye products and fluorescent metabolites were used for efficient screening of interesting clones from CYP2A6 random mutant libraries (Nakamura et al., 2001; Kim et al., 2005). Also, CYP-mediated mutagenic bioactivation was applied to select CYP1A2 mutants with enhanced catalytic activity (Kim and Guengerich, 2004b). Three consecutive
rounds of random mutagenesis and screening yielded a highly improved CYP1A2 mutant with a >10-fold increase in the bio-activation of aromatic amine based on the genotoxicity assay and a 12-fold enhanced catalytic efficiency in steady-state analysis (Kim and Guengerich, 2004b).

Recently, many luminogenic CYP assays were introduced using various prosubstrates for the light-generating reaction of firefly luciferase. The general principle is that CYPs convert prosubstrates to an active luciferin, which produces light in the second reaction with a luciferase (Fig. 1) (Cali et al., 2006). The amount of light generated is proportional to the amount of luciferin produced by the CYP enzyme and its activity. It was shown that CYP4A11 selectively converts a luciferin derivative, 2-(6-methoxyquinolin-2-yl)-4,5-dihydrothiazole-4-carboxylic acid (Luciferin-4A), to quinolylluciferin, an active alternative to native beetle luciferin (Branchini et al., 1989).

In this study, we applied a luminogenic CYP substrate and identified human CYP4A11 mutants with enhanced catalytic activity using random mutagenesis and high-throughput screening. The selected mutants were evaluated for their fatty acid hydroxylation and luminescence production activities.

**MATERIALS AND METHODS**

**Chemicals**
Lauric acid, 3-(3-cholamidopropyl)dimethylammonio)-1-propanesulfonate (CHAPS), 1,2-dilauroyl-sn-glycerol-3-phosphocholine (DLPC), N, O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), NADP⁺ and NADPH were purchased from Sigma-Aldrich (St. Louis, MO, USA). Luciferin-4A (2-(6-methoxyquinolin-2-yl)-4,5-dihydrothiazole-4-carboxylic acid (Luciferin-4A), to quinolylluciferin, an active alternative to native beetle luciferin (Branchini et al., 1989).

**Construction of CYP4A11 random mutant library plasmids**

The open reading frame of human CYP4A11 was randomly mutated using the low-fidelity polymerase PCR method as previously described (Kim and Guengerich, 2004b). Random mutagenesis PCR reactions were conducted using Gene-Morph II Random Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with the following primers: 5'-AAACCACATATGGCTCTGCCTGGTTA-3' (N-terminal primer) and 5'-GTTAATGGTAGTCTAGATTAGTGGT-3' (C-terminal primer). The amplified PCR library fragment was purified and cloned into the pCW4A11 bicistronic vector (Lim et al., 2010), which also expresses NADPH-P450 reductase. The ligation mixture was transformed into *E. coli* DH10b ultracompetent cells, and then the library plasmid DNA was purified.

**Luminescence high-throughput screening**

Construction of plasmids of CYP4A11 were transformed into *E. coli* DH5α, and individual colonies were picked up and transferred to single wells of 96-microtiter plates filled with 200 μl of Terrific Broth (TB) expression media including ampicillin and supplements (0.5 mM 5-aminolevulinic acid, 1.0 mM isopropyl β-d-thiogalactoside, 1.0 mM thiamine, and trace elements). For each generation of library screening, ~1.5×10⁴ colonies were picked and the 96-well plates were incubated at 28°C for 48 hr. For the measurement of luminescent activity of mutants, M9 medium including the Luciferin-4A substrate (and glucose) was added after TB medium was removed with centrifugation. After 20 min of incubation at 37°C, the reaction was stopped with the addition of Luciferin Detection Reagent (including luciferase, CYP-Glo™ Screening System) and further incubated at room temperature for 20 min to stabilize the luminescent signal. Luminescence was detected using a 96-microtiter luminometer (Veritas, Promega).

**Protein expression and purification**

Expression and purification of CYP4A11 mutants were carried out as previously described with some modifications (Kim et al., 2005). The *E. coli* DH5α strains transformed with pCW vectors were inoculated into LB medium containing 50 μg/ml ampicillin and incubated overnight at 37°C. LB cultures were then seeded into 500 ml of Terrific broth (TB) expression medium containing 50 μg/ml ampicillin. The expression cultures were grown at 37°C with shaking at 250 rpm. When the OD₆₀₀ of the cultures reached 0.5, supplements were added, and the expression cultures were further grown at 28°C with shaking at 200 rpm for 48 hr. Bacterial inner membrane fractions containing CYP4A11 wild type and mutants were isolated and prepared from TB expression cultures, by the method described previously (Han et al., 2009). The prepared membrane fractions were solubilized overnight at 4°C in 100 mM potassium phosphate buffer (pH 7.4) including 20% glycerol, 0.1 mM EDTA, 10 mM β-mercaptoethanol, and 1.5% CHAPS (w/v). Purification of enzymes using a Ni²⁺-nitrilotriacetate column eluted with 300 mM imidazole, was also performed using a previously described method (Yun et al., 2000).
Analysis of lauric acid hydroxylation using GC-mass spectrometry

Lauric acid hydroxylation activity was determined by GC-mass spectrometry as described (Han et al., 2009). The reaction mixtures consisted of 0.1 mM purified P450 protein in 100 mM potassium phosphate buffer (pH 7.4) including 0.2 mM rat NADPH-P450 reductase, DLPC (0.1 mg/ml), 0.1 mM cytochrome b5, and 500 μM of dithiothreitol (DTT), and varying concentrations of lauric acid in a total volume of 0.5 ml. The reaction was initiated by adding an NADPH-generating system [0.5 mM NADP+, 10 mM glucose 6-phosphate, and 1.0 IU glucose 6-phosphate dehydrogenase mL⁻¹] at 37°C and terminated with addition of 1 ml of CH₂Cl₂ after 20 min. The CH₂Cl₂ extract was dried under N₂ and then converted to trimethylsilyl derivatives by incubation with 50 μl of N,O-bis(trimethylsilyl)trifluoroacetamide at 70°C for 10 min. The derivatized samples were analyzed on the Varian 240 ion-trap gas chromatograph mass spectrometry system.

Substrate binding spectral titration

Purified CYP4A11 mutant enzymes were diluted to 2 μM in 100 mM potassium phosphate buffer (pH 7.4) and then divided between two glass cuvettes. Spectral changes (from 350 to 500 nm) were recorded with subsequent addition of lauric acid in methanol using a CARY 100 spectrophotometer (Varian). Binding affinities were estimated by fitting the data of absorbance difference to the quadratic equation using nonlinear regression analysis with Graph-Pad Prism software (GraphPad, San Diego, CA, USA).

RESULTS

Random mutagenesis and selection of CYP4A11 mutants

Random mutant library of CYP4A11 in pCW bicistronic vectors was successfully generated in the error-prone PCR reaction. The constructed mutant library was screened for mutant clones with activity to produce increased luminescence (Fig. 1). About 1.5×10⁶ clones were screened in the 1st generation mutant library, and putative 28 mutants were selected and verified as positive clones with the enhanced activity (Fig. 2). CP2600 mutant showed highly enhanced activity to produce luminescence among the selected 1st generation mutants. CP2600 mutant had double mutations, A24T and T263A. Interestingly, Ala24 was not the native sequence of CYP4A11 but a part of N-terminal modified sequence to increase the expression level of recombinant proteins (Han et al., 2009). CP2601 mutant which has only T263A mutation was generated using the site-directed mutation of CP2600 mutant. CP2616 mutant was selected from the consecutive screening analysis of additional random mutant library generated using CP2600 mutant as a PCR template. It contained triple mutations V430E as well as A24T and T263A (which were found in CP2600). Enhanced luminescence was no longer observed in the consecutive screening of random mutant library generated from CP2616 mutant.

Luminescence production by selected CYP4A11 mutants

CYP4A11 wild type and the selected mutants were expressed in large scale. The expression levels ranged from 63 to 172 nmol/liter culture (Fig. 3A). Recombinant proteins of CYP4A11 wild type and three mutants were purified using a Ni²⁺-NTA affinity chromatography column. The concentrations of all purified proteins were spectroscopically determined to be
in the range of 4.3-15 μM (Fig. 3B). These results suggested that three mutations partially affected the structural stability of the recombinant CYP4A11 protein. Demethylation activity of Luciferin-4A [2-(6-methoxyquinolin-2-yl)-4, 5-dihydrothiazole-4-carboxylic acid] was measured using purified CYP4A11 mutant proteins after normalizing the CYP holoenzyme levels (based on CO-binding spectrum). Purified CP2600 and CP-2601 mutants showed >10-fold increases, but CP2616 mutant increased only ~3 fold (Fig. 4).

Lauric acid hydroxylation activities of selected CYP4A11 mutants

Hydroxylation of lauric acid is a typical enzymatic activity of CYP4A11. In GC-mass spectrometry analysis, CYP4A11 produced mainly ω-hydroxylated lauric acid as a major metabolite at 22 min (Fig. 5). All three mutants showed significant reductions of lauric acid hydroxylation activities in the steady state kinetic analysis (Fig. 6, Table 1). CP2600 mutant showed a 51% decrease in catalytic efficiency ($k_{cat}/K_m$) for lauric acid hydroxylation mainly due to an increase in $K_m$ value. CP2601 and CP2616 showed much greater reductions in catalytic efficiency (17-25% of wild-type) due to both decreased $k_{cat}$ and increased $K_m$ (Fig. 6, Table 1).

Lauric acid binding affinities of selected CYP4A11 mutants

Binding titration of lauric acid to CYP4A11 wild type and mutants showed a typical type I spectral change (data not shown). Binding affinities of purified CYP4A11 wild type and mutants for lauric acid were determined (Fig. 7 and Table 2). The binding of lauric acid to CYP4A11 wild type yielded a $K_d$ value of 5.6 ± 0.6 μM (Table 2). CP2600 mutant showed stronger binding with a $K_d$ value of 2.5 ± 0.4 μM, but CP2601 and CP2616 mutants exhibited ~2 fold increases in $K_d$ values (Table 2).

DISCUSSION

Although the directed evolution approach is a powerful tool for analyzing the structure and function relationships of proteins, no attempt has been made regarding the study of CYP4A11 due to the lack of its screening method possessing efficiency and validity. In this study, bioluminescence was used for the high-throughput screening method of CYP4A11 random mutagenesis library. Sobol et al. reported that luciferin-4A is a selective substrate for CYP4A11 among human
CYPs, which showed time dependence and a saturated hyperbolic dose response with a $K_m$ value of 80 μM (Sobol et al., 2008). This approach differs from that previously used for human CYP1A2 and CYP2A6, in which the fluorescence of specific CYP reactions was used for screening (Kim and Guengerich, 2004a; Kim et al., 2005). The current study identified three CYP4A11 mutants with enhanced luminescence producing activity, CP2600 (A24T/T263A), CP2601 (T263A), and CP2616 (A24T/T263A/V430E), with a ~3-fold increase in whole cells and a >10-fold increase in purified proteins.

Lauric and arachidonic acid are typical substrates for human CYP4A11. Enhancement of catalytic activity in selected mutants was not observed for the hydroxylation of lauric acid. Increased catalytic activity is selective for the luciferin-4A substrate. Luciferin-4A is a quinoline structure and this significant structural difference from lauric acid (or arachidonic acid) may contribute to the changing catalytic activity of selected mutants for lauric acid. This finding supports the previous caveat that the effects of any particular mutation are relatively unique to enzyme-substrate complementarity and may diverge with different substrates (Kim and Guengerich, 2004b). Weaker affinities of lauric acid to CP2601 and CP2616 mutants may have an effect on the decreased catalytic activity to some extent albeit the stronger binding to CP2600 mutant (Table 2).

Table 1. Steady-state kinetic parameters of hydroxylation of lauric acid by purified CYP4A11 wild type and mutants

| CYP4A11 mutants | Mutations                      | $k_{cat}$ (min$^{-1}$) | $K_m$ (μM) | $k_{cat}/K_m$ Folds |
|-----------------|-------------------------------|------------------------|------------|---------------------|
| WT              | -                             | 17.1 ± 0.8             | 19.1 ± 4.5 | 0.89                |
| CP2600          | A24T/T263A                    | 14.2 ± 0.8             | 32.6 ± 7.5 | 0.44                |
| CP2601          | T263A                         | 6.3 ± 0.4              | 29.0 ± 9.0 | 0.22                |
| CP2616          | A24T/T263A/V430E              | 8.7 ± 0.7              | 58.0 ± 17.2| 0.15                |

Results are presented as means ± SD of duplicate assays.

Table 2. Estimated lauric acid binding affinities of CYP4A11 wild type and mutants

| CYP4A11 mutants | Mutations                      | $K_d$, μM |
|-----------------|-------------------------------|-----------|
| WT              | -                             | 5.6 ± 0.6 |
| CP2600          | A24T/T263A                    | 2.5 ± 0.4 |
| CP2601          | T263A                         | 12.6 ± 1.9| 1.9 ± 1.3 |
| CP2616          | A24T/T263A/V430E              | 13.2 ± 2.9| 2.9 ± 2.9 |

...continued from previous page...

In conclusion, we selected and analyzed mutant enzymes from CYP4A11 through directed evolution using a luminescent substrate. The enhanced enzymatic activity of CYP4A11 mutants for the luminescent substrate was not in accordance with lauric acid hydroxylation. Further investigation of CYP4A11 luminescent probe for application to directed evolution is required to warrant the correlation with its physiological substrate. Possibly, the fatty acid derived luminescent substrate with a comparative activity of lauric acid hydroxylation can be an alternative substrate for the high-throughput screening of CYP4A11 mutant library.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) Grants funded by the Korea government (NRF-2010-0021785).

REFERENCES

Adas, F., Salaun, J. P., Berthou, F., Picart, D., Simon, B. and Amet, Y. (1999) Requirement for omega and (omega-1)-hydroxylations of fatty acids by human cytochromes P450 4A5 and 4A11. J. Lipid Res. 40, 1990-1997.

Branchini, B. R., Hayward, M. M., Bamford, S., Brennan, P. M. and Lajiness, E. J. (1989) Naphthyl- and quinolylluciferin: green and red light emitting firefly luciferin analogues. Photochem. Photobiol. 49, 689-695.

Cali, J. J., Ma, D., Sobol, M., Simpson, D. J., Frackman, S., Good, T. D., Daily, W. J. and Liu, D. (2006) Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol. 2, 629-645.

Gainer, J. V., Bellamine, A., Dawson, E. P., Wombke, K. E., Grant, S. W., Wang, Y., Cupples, L. A., Guo, C. Y., Demissie, S., O'Donnell, C. J., Brown, N. J., Waterman, M. R. and Capdevilla, J. H. (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid...
synthase is associated with essential hypertension. *Circulation* 111, 63-69.

Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry (P. R. Ortiz de Montellano, Ed.), pp. 377-551. Plenum Press, New York.

Han, S., Eun, C.-Y., Han, J.-S., Chun, Y.-J., Kim, D.-H., Yun, C.-H. and Kim, D. (2009) Self-sufficient catalytic system of human cytochrome P450 4A11 and NADPH-P450 reductase. *Biomol. Ther.* 17, 156-161.

He, X., Cryle, M. J., De Voss, J. J. and de Montellano, P. R. (2005) Calibration of the channel that determines the omega-hydroxylation regiospecificity of cytochrome P4504A1: catalytic oxidation of 12-halobdocanoic acids. *J. Biol. Chem.* 280, 22697-22705.

Kim, D. and Guengerich, F. P. (2004a) Enhancement of 7-methoxresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding. *Arch. Biochem. Biophys.* 432, 102-108.

Kim, D. and Guengerich, F. P. (2004b) Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation. *Biochemistry* 43, 981-988.

Kim, D., Wu, Z. L. and Guengerich, F. P. (2005) Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. *J. Biol. Chem.* 280, 40319-40327.

Lee, H., Park, H. G., Lim, Y. R., Lee, I. S., Kim, B. J., Seong, C. H., Chun, Y. J. and Kim, D. (2012) Functional expression and characterization of recombinant NADPH-P450 reductase from Malassezia globosa. *J. Microbiol. Biotechnol.* 22, 141-146.

Lim, Y. R., Eun, C. Y., Park, H. G., Han, S., Han, J. S., Cho, K. S., Chun, Y. J. and Kim, D. (2010) Regioselective oxidation of lauric acid by CYP119, an orphan cytochrome P450 from Sulfolobus acidocaldarius. *J. Microbiol. Biotechnol.* 20, 574-578.

Nakamura, K., Martin, M. V. and Guengerich, F. P. (2001) Random mutagenesis of human cytochrome P450 2A6 and screening with indole oxidation products. *Arch. Biochem. Biophys.* 395, 25-31.

Okita, R. T. and Okita, J. R. (2001) Cytochrome P450 4A fatty acid omega hydroxylases. *Curr. Drug Metab.* 2, 265-281.

Ortiz de Montellano, P. R. (2005) Cytochrome P450: Structure, Mechanism, and Biochemistry. Plenum Press, New York.

Park, H. G., Lim, Y. R., Eun, C. Y., Han, S., Han, J. S., Cho, K. S., Chun, Y. J. and Kim, D. (2010) Candida albicans NADPH-P450 reductase: expression, purification, and characterization of recombinant protein. *Biochem. Biophys. Res. Commun.* 396, 534-538.

Pylypenko, O. and Schlichting, I. (2004) Structural aspects of ligand binding to and electron transfer in bacterial and fungal P450s. *Annu. Rev. Biochem.* 73, 991-1016.

Sobol, M., Ma, D. and Cali, J. J. (2008) Selective cytochrome P450 4A11 enzyme assay using a novel bioluminescent probe substrate. Promega. [Internet] Available from: http://ita.promega.com/resources/pubhub/enotes/selective-cytochrome-p450-4a11-enzyme-assay-using-a-novel-bioluminescent-probe-substrate/

Yun, C.-H., Miller, G. P. and Guengerich, F. P. (2000) Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. *Biochemistry* 39, 11319-11329.